According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
Other analysts have also issued reports about the company. Wedbush restated a neutral rating and issued a $18.00 price target on shares of Omeros in a report on Monday, July 15th. ValuEngine upgraded Omeros from a hold rating to a buy rating in a report on Thursday, August 1st. HC Wainwright set a $35.00 price target on Omeros and gave the company a buy rating in a report on Tuesday, May 28th. Cantor Fitzgerald began coverage on Omeros in a research report on Monday, May 6th. They issued an overweight rating and a $26.00 target price on the stock. Finally, BidaskClub raised Omeros from a sell rating to a hold rating in a research report on Tuesday, July 30th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $25.80.
Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.15. The firm had revenue of $26.80 million during the quarter, compared to the consensus estimate of $25.33 million. The business’s revenue for the quarter was up 1476.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.70) earnings per share. As a group, equities analysts forecast that Omeros will post -1.68 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. Aperio Group LLC acquired a new stake in shares of Omeros in the second quarter valued at about $49,000. Advisory Services Network LLC acquired a new stake in shares of Omeros in the first quarter valued at about $69,000. Legal & General Group Plc increased its position in shares of Omeros by 12.7% in the fourth quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 945 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Omeros by 16,167.2% in the first quarter. BNP Paribas Arbitrage SA now owns 9,923 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 9,862 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in shares of Omeros by 417.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,004 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 12,911 shares during the last quarter. 51.64% of the stock is currently owned by institutional investors and hedge funds.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Further Reading: Is it better to buy a fund with a higher or lower NAV?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.